This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates that may be more effective than Wegovy. In a Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after the start of treatment.
Amid calls to expand access to medicines in low- and middle-income countries, a new analysis finds that most of the world’s 20 largest pharmaceutical companies have taken steps to reach patients, but many efforts are yielding decidedly mixed results. On the one hand, 19 companies have established methods for providing treatments to these countries — but only nine of the drugmakers created comprehensive plans.
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
PROVIDENCE, R.I. — In a cavernous converted chapel at Brown University, physician and data scientist Leo Celi observed from the sidelines as a tableful of high school students passed around a plastic, crocodilian device. The pulse oximeter clamped down on one student’s fingertip: Ninety-seven, he read out loud, before handing it off to the student next to him.
The first late-stage trial of a GLP-1 drug in young children with obesity showed the treatment helped lower body mass index. But the findings also raise questions about whether obesity medications, some of which are currently approved for teenagers, should also be given to children at such a young age. The 56-week trial tested Novo Nordisk’s Saxenda, the predecessor of Wegovy, coupled with lifestyle interventions in children ages 6 to 12.
For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged. Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs
The General Pharmaceutical Council (GPhC) will release a consultation on changes to guidance for online pharmacies 'within the next couple of weeks', chief executive Duncan Rudkin has said. Proposed changes will emphasise the importance of a 'two-way dialogue between patients and prescriber', which may require further interaction beyond an asynchronous questionnaire, Mr Rudkin suggested.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Two former Verily executives say that they are starting a new initiative, Highlander Health, to push forward an effort decades in the making: making it so that the records collected in hospitals can be used in real-time to advance science, decreasing the cost of conducting clinical trials and speeding medical progress while helping patients get the right drug for them.
Community Pharmacy England (CPE) is concerned that local pharmacies may walk away from delivering Pharmacy First consultations if they cannot reach the thresholds for the £1,000 monthly payment. Speaking at the Avicenna Heathrow conference this weekend (8 September), CPE's director of NHS services Alastair Buxton said the number of clinical pathway consultations required for the […] The post CPE concerned pharmacies will 'walk away' from Pharmacy First appeared first on The Pharm
Seven years after the FDA approved Luxterna , scientists have yet to bring another congenital blindness treatment to the market. A team of researchers from the Perelman School of Medicine at the University of Pennsylvania aims to change this. The group recently published a study in The Lancet documenting their success using gene therapy to treat an inherited retinal blindness that affects as many as 100,000 people globally.
Investment in life sciences real estate is booming as the industry faces the looming 'patent cliff' Learn about the current trends and what lies ahead for this sector.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
What does it cost to have a baby in the United States? This question has always vexed me. I’ve tried unsuccessfully to prospectively price deliveries for family and friends over the years. After insurance, deliveries can range from a few hundred dollars to a couple of thousand. If you’re underinsured or have a more complex birth, it can cost more than $10,000 out of pocket.
This is Part 4 of “ Behind the Counter ,” an in-depth video series demystifying the complex world of patents and drug pricing. Years ago, when a brand-name medication’s patent expired, consumers had to wait a long time for a more affordable generic version to come to market. But in 1984, a little-known law put an end to that waiting period and paved the way for the large quantity of generic drugs available today.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
WASHINGTON – Powerful House lawmakers from both parties are skeptical of the Food and Drug Administration’s pitch to start collecting fees from e-cigarette companies, similar to how the agency assesses them on tobacco firms. FDA officials say that the fees, which e-cigarette companies would pay when filing applications with the agency, would give regulators resources to tackle the thousands of illegal vapes lining store shelves.
Elevance Health, the parent of more than a dozen state Blue Cross Blue Shield plans, is purchasing Indiana University Health’s insurance business in a deal that would increase its dominance in several key cities in the state. IU Health’s decision to sell is the latest and most prominent example of hospital systems giving up on the idea that they can be both a provider and payer of care.
A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Flare Capital ‘s new examination of 4,000 healthcare AI venture capital deals looked at where investment has actually created value — that is, what early-stage, venture-backed technology matures enough to impact the health care ecosystem?
The generic drug market has experienced significant growth over the past few decades, driven by the passage of the Hatch-Waxman Act in 1984 and subsequent legislation. Today, the market is more competitive than ever, with generic drugs accounting for over 90% of all prescriptions in the United States.
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on Wednesday, bringing the firms closer to securing Food and Drug Administration approval after the agency rejected their application last year. In the Phase 3 trial, dubbed Liberty-Cupid Study C, patients took antihistamines, the current standard of care, and Dupixent or a placebo.
Bothnia dystrophy is a form of hereditary blindness, prevalent in the region Västerbotten in Sweden. A new study at Karolinska Institutet published in Nature Communications shows that gene therapy can improve vision in patients with the disease. Bothnia dystrophy occurs mainly in the region Västerbotten in Sweden, but the disease has also been identified in other parts of the world.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
340 
Let's personalize your content